The Enduring Success of Hybridoma-based Antibody Development
White Paper Aug 14, 2019
Since its original development in 1975, hybridoma technology encourages researchers all over the world to share their antibodies with one another, unlocking a vast amount of potential for biological research.
Due to their high selectivity, monoclonal antibodies (mAbs) are used in a wide range of disciplines, including research, diagnostics and therapeutic applications. Despite the advancement of modern antibody generation technologies, hybridoma-based antibody production continues to be a leading approach for mAb discovery and development.
Download these whitepapers to explore:
- The key benefits of using hybridoma-based antibody development
- Perceived misconceptions relating to hybridoma technology
- Alternative approaches that currently exist for mAb generation
Related White Papers
Download this white paper to understand how PerkinElmer’s Lead Discovery Premium can help deliver unified, interactive, responsive, data-agnostic access to all users.
READ MOREDownload this whitepaper to explore the shortcomings of LIMS when it comes to managing microbiology processes and learn of ways to overcome associated challenges.
READ MOREDownload this whitepaper to uncover: the fundamentals of MMA, the factors affecting MMA, and how Q-TOF MS achieves sub-ppm MMA.
READ MORELike what you just read? You can find similar content on the communities below.
Cell Science Drug Discovery Immunology & MicrobiologyTo personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free
LOGIN SUBSCRIBE FOR FREE
